We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cymabay Therapeutics Inc (CBAY) USD0.0001

Sell:$32.47 Buy:$32.48 Change: $0.005 (0.02%)
NASDAQ:0.82%
Market closed |  Prices as at close on 18 March 2024 | Switch to live prices |
Takeover

Cymabay Therapeutics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 7 Mar 2024)

Pacific Merger Sub, a wholly owned subsidiary of Gilead Sciences Inc, has made an offer to buy Cymabay Therapeutics Inc shares for USD32.50 per share.

 

If you don’t want to accept the offer, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Monday 18 March 2024

 

The proceeds will be converted to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:$32.47
Buy:$32.48
Change: $0.005 (0.02%)
Market closed |  Prices as at close on 18 March 2024 | Switch to live prices |
Takeover

Cymabay Therapeutics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 7 Mar 2024)

Pacific Merger Sub, a wholly owned subsidiary of Gilead Sciences Inc, has made an offer to buy Cymabay Therapeutics Inc shares for USD32.50 per share.

 

If you don’t want to accept the offer, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Monday 18 March 2024

 

The proceeds will be converted to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:$32.47
Buy:$32.48
Change: $0.005 (0.02%)
Market closed |  Prices as at close on 18 March 2024 | Switch to live prices |
Takeover

Cymabay Therapeutics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 7 Mar 2024)

Pacific Merger Sub, a wholly owned subsidiary of Gilead Sciences Inc, has made an offer to buy Cymabay Therapeutics Inc shares for USD32.50 per share.

 

If you don’t want to accept the offer, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Accept the offer – Act by noon on Monday 18 March 2024

 

The proceeds will be converted to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.

Contact details

Address:
SUITE 130, 7999 GATEWAY BLVD
NEWARK
94560
United States
Telephone:
+1 (510) 2938800
Website:
https://www.cymabay.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CBAY
ISIN:
US23257D1037
Market cap:
$3.72 billion
Shares in issue:
114.79 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Sujal Shah
    President, Chief Executive Officer, Director
  • Harish Shantharam
    Chief Financial Officer
  • Charles McWherter
    President of Research and Development, Chief Scientific Officer
  • Paul Quinlan
    Chief Compliance Officer, General Counsel, Corporate Secretary
  • Klara Dickinson
    Chief Regulatory and Quality Assurance Officer
  • Lewis Stuart
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.